-
Do patients with diabetes share in the reduction of cardiovascular (CV) risk factors as much as non-diabetics?
-
Dual antiplatelet therapy with aspirin and clopidogrel has become the standard of care for patients suffering an acute coronary syndrome (ACS). However, there remains a significant incidence of recurrent ACS and mortality even in patients treated with dual antiplatelet therapy.
-
The ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) series of randomized, controlled trials has assessed the role of atorvastatin loading prior to percutaneous coronary intervention (PCI) in both stable and unstable coronary syndromes.
-
-
Folke et al from Copenhagen, Denmark, studied the consequences of automatic external defibrillator (AED) placement in a large metropolitan area.
-
Current recommendations for stroke prophylaxis with warfarin for patients with atrial fibrillation do not take into account the risks of hemorrhage.
-
Based upon an increased incidence of heart failure with alpha 1-adrenergic antagonists treatment of hypertension, there has been concern about using alpha blockers for benign prostatic hypertrophy (BPH) in patients with heart failure, yet these drugs are highly efficacious for this common condition.
-
Tamoxifen and CYP2D6 inhibitors, FDA Actions, and FDA Warnings.
-
-
In this paper, Krahn et al from a Canadian consortium report on the results of systematic evaluations in patients with unexplained cardiac arrest due to ventricular tachycardia or ventricular fibrillation.